Germany: Claim interpretation if preamble equates to state of the art

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Germany: Claim interpretation if preamble equates to state of the art

When interpreting a patent claim, it must be taken into account that a patent's doctrine seeks to distinguish itself from the state of the art described in it. If the specification equates to known prior art with the claim's preamble, the features of the characterising portion of the patent shall – in case of doubt – not be regarded as being understood according to features which are found in the state of the art from which they currently should have been distinguished. (Guiding principle of the Court)

PatG § 14; EPÜ Art. 69; BGH X ZR 16/17 (BPatG) – Scheinwerferbelüftungssystem

The defendant was the proprietor of European patent 0 764 811, relating to headlamps of motor vehicles with a ventilation system, which had meanwhile expired. An action for annulment will continue to be admissible owing to the fact that a declaration of invalidity of the patent in dispute opened up the possibility for the plaintiff to bring an action for restitution against its judgment.

The description of the patent in dispute was adapted in the course of the grant procedure to note that the expert was aware of a ventilation system, according to the preamble of independent patent claim 1 from a French patent application belonging to the state of the art. In the course of the grant procedure claim 1 was changed into a two-part form. The characteristic part of claim 1 of the patent in dispute provides, inter alia, that the ventilation system forms a labyrinth, with a twofold change of direction of the ventilation path.

The plaintiff asserts that such a labyrinth, with a twofold change of direction, is shown in the French patent application cited, which is why the subject matter of the patent at issue is not patentable owing to a lack of novelty, or at least due to a lack of inventive step. The BPatG dismissed the request.

The nullity appeal was directed against this judgement and the plaintiff continued to seek the full nullity of the patent in dispute.

The BGH rejected the appeal.Consequently, in nullity proceedings a novelty attack based on prior art cited in the patent specification might, in case of doubt, not be successful if the prior art in the patent is equated with the preamble of the claim as explained in this decision. On the other hand, a restrictive interpretation of the claims can be made in equivalent cases for infringement proceedings

tegeder-volker.jpg

Volker Tegeder


Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbHElisenhof, Elisenstr 3D-80335, Munich, GermanyTel: +49 89 74 72 660 Fax: +49 89 77 64 24info@maiwald.euwww.maiwald.eu

more from across site and SHARED ros bottom lb

More from across our site

News of Avanci hiring a senior vice president and the EPO teaming up with a French AI startup were also among the top talking points
Explosm, the independent Texas studio behind the hit webcomic Cyanide & Happiness, partnered with Temu’s IP protection team to combat counterfeiters infringing on its brand
The latest in a dispute over juicing machines, and a shakeup in judicial compositions were also among the top developments
Patent partner Robert Hollingshead explains why the firm remains committed to Japan despite several US firms exiting the Japanese and greater Asia market
Emma Green, partner at Bird & Bird, shares why the Iceland v Iceland dispute could prompt businesses and lawyers to think differently about brand enforcement
Attain IP, developed by two UK patent lawyers, will meet ‘forensic’ needs of patent attorneys by showing a verifiable reasoning chain, according to its co-founders
The High Court of Australia has allowed a fashion designer to retain her registered ‘Katie Perry’ trademark for clothing
Sim & San secured the win for Dr. Reddy’s, which will allow the pharma company to manufacture and export semaglutide, the active ingredient in Ozempic
Lucas Amodio joins our ‘Five minutes with’ series to discuss artificial intelligence systems and patent law
The Americas research cycle has commenced, so don't miss the opportunity to submit your work
Gift this article